Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 20/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5365987 | 0.90 | GRIN2B (0.72) | GRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL5357717 | 0.89 | GRIN2B (0.73) | GRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL5356269 | 0.83 | GRIN2B (0.60) | GRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL5354371 | 0.81 | GRIN2B (0.71) | GRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL5346958 | 0.81 | GRIN2B (0.71) | GRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL5354026 | 0.80 | GRIN2B (0.74) | GRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL5347561 | 0.78 | GRIN2B (0.74) | GRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL14502214 | 0.77 | GRIN2B (0.69) | GRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL5358124 | 0.77 | GRIN2B (0.69) | GRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL5366730 | 0.77 | GRIN2B (0.68) | GRIN2BCYP2D6CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040204341-A1 | Nr2b receptor antagonists for the treatment or prevention of migraines | ALLEN CHRISTOPHER (US) | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204341-A1 | Nr2b receptor antagonists for the treatment or prevention of migraines | HTR1B, HTR2B, HTR1A | GRIN2B 4/4885CYP2D6 1690/4885CYP2C9 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.